Actively Recruiting
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
Led by Shenzhen Geno-Immune Medical Institute · Updated on 2026-04-24
20
Participants Needed
2
Research Sites
189 weeks
Total Duration
On this page
Sponsors
S
Shenzhen Geno-Immune Medical Institute
Lead Sponsor
T
The No.2 Clinical Hospital of the Ministry of Health
Collaborating Sponsor
AI-Summary
What this Trial Is About
The aim of this clinical trial is to assess the feasibility, safety, and efficacy of CAR-T cell therapy targeting multiple cancer cell antigens in high-risk multiple myeloma or plasmacytoma as part of a frontline treatment regimen for patients. Another goal of the study is to learn more about the persistence and function of these CAR-T cells in the body.
CONDITIONS
Official Title
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male and female subjects with multiple myeloma or plasmacytoma
- Strictly complete remission (sCR) is a treatment goal
- Expected survival greater than 12 weeks
- Eligible after prior autologous stem cell transplant regardless of other prior therapies
- Adequate venous access for apheresis and no contraindications for leukapheresis
- Voluntary informed consent given and commitment to continued follow-up
You will not qualify if you...
- Pregnant or lactating women
- Uncontrolled active infection
- Active HIV, hepatitis B or hepatitis C infection
- Concurrent use of systemic steroids (recent or current use of inhaled steroids is allowed)
- Any medical conditions that may preclude participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Shenzhen Geno-immune Medical Institute
Shenzhen, Guangdong, China, 518000
Actively Recruiting
2
Hematologist of the Regional Hematology Center in Clinical Hospital No. 2 of the Ministry of Health
Vladivostok, Russia, 690105
Actively Recruiting
Research Team
L
Lung-Ji Chang, ph.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here